Discriminating the contribution of unmodifiable random intrinsic DNA replication errors ('bad
luck') to cancer development from those of other factors is critical for understanding cancer in …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Transcript alterations often result from somatic changes in cancer genomes. Various forms of
RNA alterations have been described in cancer, including overexpression, altered splicing …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Tau phosphorylation is regulated by a balance between tau kinase and phosphatase
activities. Disruption of this equilibrium was suggested to be at the origin of abnormal tau …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

Background BCR-ABL is a constitutively activated tyrosine kinase that causes chronic
myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming …

Mass spectrometry (MS)-based phosphoproteomics has achieved extraordinary success in
qualitative and quantitative analysis of cellular protein phosphorylation. Considering that an …

Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia
demonstrate that many patients with advanced stage disease respond initially but then …